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The current regulatory guideline focusses on the inclusion of geriatric patients in clinical trials. However, the geriatric population represents a 
heterogeneous group of patients requiring a more individual therapy, administered in an appropriate, high quality formulation, enabling optimal healthcare.  
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INTRODUCTION  
OBJECTIVE 
RESULTS and DISCUSSION  
CONCLUSION 
REFERENCES 
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Source: http://www.fdbetancor.com/2012/06/04/the-american-century/ (accessed 05/10/2014) 
• Demographic trend: increase in age group > 65 y   decrease in birth rate.  
• Geriatric patients = heterogeneous group:  
o Inter-individually varying effects of aging (i.a. PK/PD changes due to altered organ functions) 
o Co-morbidity 
o Polypharmacy 
• Elderly patients are main users of drugs: use 30-50% of prescription drugs. 
• Old adults are underrepresented in clinical trials  lack of evidence-based medicine in this population. 
1. What is the current regulatory status of geriatric medicines? 
2. What are the current views of different stakeholders on the development and regulation on geriatric medicines. 
3. What are the current challenges in the regulatory development of geriatric medicines. 
ICH E7 guideline 
+ Questions and Answers document 
European Medicines 
Agency (EMA) 
Food and Drug 
Administration (FDA) 
Pharmaceutical and Medical 
Device Agency (PMDA) 
• Geriatric medicines strategy. 
• Geriatric expert group. 
• FDA guidance and regulations related to data on elderly 
persons in clinical drug trials (GAO-07-47R). 
• No additional strategy for geriatric medicines. 
VIEWS OF DIFFERENT STAKEHOLDERS 
CURRENT CHALLENGES 
To GIP or  
not to GIP? 
• Altered blood-brain barrier permeability 
• Altered skin barrier permeability 
• Changes in gut microbiota 
         … 
• Focus on clinical trials 
• Geriatric patients = aged >65   
o older old >75 y 
o “frail” patients 
adopted by 
Studies in support of special 
populations: geriatrics 
INDUSTRY HEALTHCARE PROVIDERS REGULATORS 
REGULATORY STATUS  Paediatric medicines (PIP) 
subgroups 
• Specific regulatory guidance 
needed. 
• Engagement to address 
special needs of geriatric 
patients   delay development 
of new drugs. 
• Lack of relevant information to 
appropriately prescribe to the 
elderly in the clinical practice. 
• No formal requirements. 
• No need for specific 
regulations. 
Age-related functional changes 
Pharmaco-economics 
Personalized medicine 
Heterogeneity Clinical trials 
Age-appropriate drug 
formulations 
Ethics 
• Development cost 
• Social security 
• Cost savings for 
medicines 
  … 
                 … 
• Individualization 
• Biomarkers 
       … 
• Stratification during clinical trials 
   … 
• Swallowability of drug 
• Manageability of 
packaging 
• Complexity of drug 
therapy (polypharmacy) 
• Appropriate dose 
strength  
  … 
• Competence  
• Informed consent 
• Benefit/risk 
• No evidence-based 
medicine for elderly 
  … 
Cognitive impairment ? 
• Ethics 
• Recruitment of patients 
• Study design 
  … 
